A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Source: CNBC Business
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at CNBC Business